List of Excipients in Branded Drug BD E-Z SCRUB

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Xttrium Laboratories Inc	BD E-Z SCRUB	chlorhexidine gluconate	0116-0505	COCO DIETHANOLAMIDE
Xttrium Laboratories Inc	BD E-Z SCRUB	chlorhexidine gluconate	0116-0505	GLUCONOLACTONE
Xttrium Laboratories Inc	BD E-Z SCRUB	chlorhexidine gluconate	0116-0505	ISOPROPYL ALCOHOL
Xttrium Laboratories Inc	BD E-Z SCRUB	chlorhexidine gluconate	0116-0505	LAURAMINE OXIDE
Xttrium Laboratories Inc	BD E-Z SCRUB	chlorhexidine gluconate	0116-0505	PEG-75 LANOLIN
Xttrium Laboratories Inc	BD E-Z SCRUB	chlorhexidine gluconate	0116-0505	TRIDECYL ALCOHOL

Generic Drugs Containing BD E-Z SCRUB

Company	Ingredient	NDC	Excipient
Becton Dickinson and Company	chlorhexidine gluconate	17271-107	FD&C RED NO. 40
Becton Dickinson and Company	chlorhexidine gluconate	17271-107	HYDROCHLORIC ACID
Becton Dickinson and Company	chlorhexidine gluconate	17271-107	LAURIC DIETHANOLAMIDE
Becton Dickinson and Company	chlorhexidine gluconate	17271-107	NONOXYNOL-12
Becton Dickinson and Company	chlorhexidine gluconate	17271-107	PEG-150 DISTEARATE
Becton Dickinson and Company	chlorhexidine gluconate	17271-107	PEG-75 LANOLIN

What are the Most Frequently-Used Excipients in BD E-Z SCRUB?

# Of NDCs	Excipient

BD E-Z SCRUB Excipient Strategy and Commercial Opportunities

Last updated: August 3, 2026

BD E-Z SCRUB is a povidone-iodine surgical scrub whose commercial differentiation depends more on excipient performance, packaging, procurement economics, and regulatory execution than on patent exclusivity. Public labeling identifies povidone-iodine 7.5% as the active ingredient, with an excipient system built around a surfactant, humectant, buffering agents, sodium hydroxide, and purified water.[1]

The main opportunities are improved skin tolerability, lower-irritation surfactants, stable iodine availability, unit-dose packaging, surgical procedure kits, and geographic expansion. The product is exposed to generic and private-label competition because povidone-iodine and the underlying scrub technology are mature and generally lack meaningful compound-patent protection.

What is BD E-Z SCRUB and how is it regulated?

BD E-Z SCRUB is a topical antiseptic surgical scrub used for preoperative hand and skin cleansing. The formulation uses povidone-iodine, a complex of iodine with povidone that releases free iodine at the skin surface.

Attribute	BD E-Z SCRUB profile
Brand	BD E-Z SCRUB
Manufacturer	Becton, Dickinson and Company
Dosage form	Topical liquid surgical scrub
Active ingredient	Povidone-iodine 7.5%
Available iodine	Approximately 0.75% equivalent available iodine
Primary use	Surgical hand scrub and antiseptic skin cleansing
Regulatory category	Human topical antiseptic drug product
Commercial channel	Hospitals, ambulatory surgery centers, distributors and institutional procurement
Exclusivity basis	Product quality, brand, supply, packaging and contracts rather than meaningful patent exclusivity

The product is regulated as a topical drug. Its commercial position is distinct from chlorhexidine-based surgical preparations, which compete on residual antimicrobial activity, persistence, and clinical preference.

What excipients are used in BD E-Z SCRUB?

Public product labeling identifies the following excipient categories for the 7.5% povidone-iodine scrub formulation:[1]

Excipient or excipient class	Formulation function	Commercial relevance
Ammonium nonoxynol-4 sulfate or related nonionic/sulfated surfactant system	Wetting, cleansing, foam formation and soil removal	Potential reformulation target because surfactant selection affects irritation, foam, rinseability and supply risk
Glycerin	Humectant and skin-conditioning agent	Can reduce perceived dryness but may alter viscosity and residue
Citric acid	pH adjustment and buffering	Controls iodine stability and skin compatibility
Disodium phosphate	Buffering and pH control	Helps maintain formulation performance over shelf life
Sodium hydroxide	pH adjustment	Small concentration changes can affect iodine equilibrium and stability
Purified water	Vehicle	Controls microbial quality, iodine distribution and manufacturing consistency

The exact quantitative composition is proprietary and is not generally disclosed in commercial labeling. The excipient system must preserve free-iodine availability while producing acceptable foam, spreadability, rinsability, skin feel, color, odor, and shelf stability.

How does the excipient system work?

Povidone-iodine is a dynamic equilibrium system. The formulation must contain sufficient iodine complex to maintain antimicrobial activity without creating excessive free iodine, which can increase irritation and odor.

The surfactant is central to product performance. It determines:

• Soil removal from hands and skin
• Foam volume and persistence
• Wetting of irregular skin surfaces
• Rinseability
• Compatibility with gloves and surgical instruments
• Perceived harshness after repeated use

Glycerin supports skin feel but can increase tackiness if used at an excessive level. Buffer selection influences iodine release, color stability, and compatibility with the packaging system. Sodium hydroxide requires tight control because pH excursions can affect iodine chemistry.

What formulation patents protect BD E-Z SCRUB?

No publicly visible patent estate appears to provide durable exclusivity for the core BD E-Z SCRUB formulation. Povidone-iodine, glycerin, phosphate buffering, citric acid, water, and conventional surgical scrub surfactants are established pharmaceutical ingredients.

The likely protection profile is:

IP category	Expected strength
Povidone-iodine composition	Low; mature and widely used
Conventional surfactant system	Low to moderate, depending on narrow claim scope
Specific excipient ratios	Potentially moderate but vulnerable to design-around
Manufacturing process	Moderate if process parameters are difficult to replicate
Packaging and dispensing system	Moderate where the package reduces contamination or improves use
Brand and trade dress	More relevant than composition patents
Hospital contracts and distribution	Commercially important but not patent exclusivity
Clinical or procedural evidence	Differentiating, but not a traditional patent barrier

A competitor could likely design around a narrow formulation claim by changing the surfactant, buffer ratio, viscosity modifier, fragrance-free profile, or packaging format while retaining povidone-iodine 7.5%.

Does BD E-Z SCRUB have Orange Book protection?

BD E-Z SCRUB is not commercially positioned like a new prescription drug with listed patents and regulatory exclusivity in the FDA Orange Book. The principal competitive pathway is not a Paragraph IV challenge to a listed patent. Competition is more likely to arise through other approved or legally marketed topical antiseptic products, private-label products, institutional purchasing, and direct formulation substitution.

The Orange Book generally records approved prescription drug products and certain other approved products with related patent and exclusivity information. A mature topical antiseptic product marketed through the OTC or institutional antiseptic framework normally does not receive meaningful Orange Book-based market protection.[2]

When does BD E-Z SCRUB lose exclusivity?

BD E-Z SCRUB does not have a clear compound-patent exclusivity date comparable with a modern small-molecule prescription drug. Its effective exclusivity is already limited.

The relevant commercial timeline is:

Exclusivity element	Status
Active ingredient exclusivity	None expected; povidone-iodine is long established
Core excipient exclusivity	Limited and design-around risk is high
FDA new-drug exclusivity	No publicly evident product-specific exclusivity comparable to NCE exclusivity
Orange Book patent expiry	No central listed-patent date identified for the core product
Trademark protection	Potentially ongoing if maintained
Contractual hospital protection	Depends on purchasing agreements
Supply and quality differentiation	Ongoing but not legally exclusive

The practical loss-of-exclusivity event is therefore not a single patent expiration date. It is the entry or expansion of lower-cost povidone-iodine scrubs, chlorhexidine scrubs, private-label products, and procedure kits.

What is the FDA regulatory status of povidone-iodine surgical scrub?

Povidone-iodine has long been used in topical antiseptic products, but FDA treatment of topical antiseptic ingredients depends on the product category, indication, concentration, labeling, and applicable monograph or approval pathway.

FDA has separated consumer first-aid antiseptics from healthcare antiseptic products used by healthcare professionals. The agency has required evidence addressing safety, effectiveness, and pharmacokinetics for healthcare antiseptic ingredients, including products intended for repeated professional use.[3]

For a BD E-Z SCRUB line extension, the regulatory strategy should distinguish among:

1. Surgical hand scrub.
2. Patient preoperative skin preparation.
3. First-aid antiseptic use.
4. Healthcare-professional hand antisepsis.
5. Antiseptic washing in procedure kits.

A change in indication or active concentration can alter the applicable FDA pathway. An excipient change may also require comparative formulation, stability, microbial quality, skin irritation, packaging, and effectiveness support, even if the active ingredient remains unchanged.

What excipient changes offer the strongest commercial opportunities?

1. Lower-irritation surfactant system

The most direct opportunity is replacement or optimization of the existing surfactant system. A next-generation scrub could target:

• Lower cumulative skin irritation
• Reduced dryness after repeated surgical scrubbing
• Lower ocular and mucosal irritation risk
• Faster rinsing
• Comparable or improved foam
• Reduced residue under gloves
• Better compatibility with frequent-use protocols

The development challenge is that surfactant substitution can change iodine release, viscosity, preservative requirements, package compatibility, and antimicrobial performance.

2. Fragrance-free and low-odor formulation

Povidone-iodine products have a recognizable iodine odor and color. A fragrance-free, low-odor formulation could appeal to operating-room staff and institutions seeking improved user acceptance. Fragrance addition is generally less attractive because it can increase sensitization concerns and complicate regulatory assessment.

The strongest commercial claim would be based on user tolerability and workflow acceptance rather than an unsupported claim of superior antimicrobial efficacy.

3. Skin-conditioning system

A controlled humectant or emollient system could reduce dryness while preserving iodine availability. Candidate excipients must not bind iodine excessively, reduce free-iodine release, create a persistent film, or interfere with gloves and surgical drapes.

A skin-conditioning product could command a premium in high-frequency-use settings, including:

• Operating rooms
• Labor and delivery units
• Ambulatory surgery centers
• Intensive-care units
• Emergency departments
• Dental and outpatient procedure facilities

4. Improved rheology

A moderate increase in viscosity can improve residence time and reduce runoff. Excess viscosity can slow rinsing and increase residue. A rheology platform could support specialized products for:

• Surgical hand scrub
• Patient preoperative cleansing
• Bedside antiseptic washing
• Procedure kits
• Controlled-dose applicators

The formulation must remain pourable across the labeled temperature range and compatible with pumps, brushes, sponge applicators, and unit-dose containers.

5. Concentrate or refill system

A concentrated institutional format could reduce shipping and packaging costs, but it creates substantial validation requirements. Dilution errors, microbial contamination, iodine loss, and in-use stability become central risks.

A safer commercial approach is a ready-to-use refill pouch or cartridge that preserves the existing concentration while reducing plastic and dispensing costs.

How does BD E-Z SCRUB compare with chlorhexidine surgical scrubs?

Chlorhexidine-based products are the principal competitive benchmark in healthcare antisepsis. The comparison is formulation-specific and depends on the use case.

Factor	BD E-Z SCRUB, povidone-iodine	Chlorhexidine surgical scrub
Active chemistry	Iodine complex with released free iodine	Cationic bisbiguanide
Residual activity	Generally limited compared with chlorhexidine	Strong residual activity on skin
Broad-spectrum profile	Broad antimicrobial activity	Broad activity, with limitations against some organisms
Organic material sensitivity	Performance can be affected by organic load	Also affected by formulation and use conditions
Skin tolerability	Can cause dryness or irritation with repeated use	Can cause irritation and serious ocular/ototoxicity concerns in certain exposures
Staining	Characteristic iodine color	Usually less visible staining
Institutional preference	Often selected where iodine is preferred or chlorhexidine is unsuitable	Frequently preferred for persistent antimicrobial effect
Excipient opportunity	Surfactant, humectant, buffer and package optimization	Similar, with additional compatibility and safety constraints

The commercial opportunity for BD E-Z SCRUB is strongest where institutions value iodine chemistry, require an alternative to chlorhexidine, or need a lower-cost product with broad procedural applicability.

What generic entry risks exist for BD E-Z SCRUB?

Generic and private-label risk is high at the ingredient level and moderate at the finished-product level.

Primary sources of competition

• Generic povidone-iodine surgical scrubs
• Hospital private-label antiseptic products
• Contract-manufactured surgical scrub
• Chlorhexidine alternatives
• Antiseptic scrub brushes and sponge applicators
• Integrated preoperative preparation kits
• International products using local brands
• Bulk institutional formats

The main barriers are not active-ingredient patents. They are manufacturing validation, consistent iodine assay, color and odor control, package compatibility, microbial quality, procurement qualification, and hospital switching costs.

A competitor can enter with a conventional formulation but may face lengthy hospital evaluation cycles. Hospitals often assess skin tolerability, staff acceptance, packaging reliability, infection-control protocols, reimbursement or supply-chain implications, and total cost per procedure.

Which companies are challenging BD E-Z SCRUB?

Competition is likely to come from manufacturers of povidone-iodine and chlorhexidine antiseptic products rather than from a single Paragraph IV challenger. Relevant competitive groups include:

• Large hospital-supply companies
• Generic topical drug manufacturers
• Private-label suppliers
• Surgical preparation kit manufacturers
• Specialty antiseptic companies
• Regional manufacturers in Europe, Asia and Latin America

Betadine-branded products from Kenvue or related legacy Johnson & Johnson operations are a major commercial reference point for povidone-iodine. Chlorhexidine products from companies such as BD, Mölnlycke, Cardinal Health and other healthcare suppliers compete for the same institutional budgets, although product availability and ownership vary by market and date.

What manufacturing and IP barriers affect commercial expansion?

The main manufacturing risks are chemical and operational.

Iodine stability

Manufacturers must control iodine content, pH, temperature exposure, light exposure, container closure interaction, and headspace conditions. Iodine can migrate, volatilize, or interact with excipients and packaging materials.

Surfactant supply

Specialty surfactants can create supplier concentration risk. A second-source strategy should demonstrate equivalent cleansing, foaming, iodine release, skin compatibility, and stability.

Packaging compatibility

Plastic selection is material to product quality. The package must limit iodine adsorption, discoloration, permeation, leakage, and extractables. Pump and brush components require separate compatibility testing.

Microbial quality

Although povidone-iodine is antimicrobial, the finished product still requires appropriate manufacturing controls. The formulation, closure, dispensing system, and in-use period must be assessed for contamination risk.

Process know-how

Manufacturing know-how may be more valuable than patent claims. Addition order, mixing energy, temperature control, hydration time for povidone, pH adjustment, and filling conditions can affect batch uniformity and iodine assay.

What licensing and partnering opportunities exist?

No major public licensing arrangement is required to commercialize a conventional excipient improvement, but partnering can accelerate market access.

Potential structures include:

Partner type	Opportunity
Specialty excipient supplier	Co-development of a lower-irritation surfactant or skin-conditioning platform
Contract manufacturer	Regional production and regulatory filing support
Surgical kit company	Inclusion in preoperative preparation kits
Hospital distributor	Institutional conversion and formulary access
Packaging company	Unit-dose, refill, pump or brush-system development
Contract research organization	Comparative irritation, stability and antimicrobial testing
Regional pharmaceutical company	Local registration and distribution rights

The strongest licensing asset would be a validated formulation platform with comparative data, not a simple substitution of one commodity excipient for another.

How strong is the BD E-Z SCRUB patent estate?

The patent estate is likely weak for the core product and stronger for selected delivery or packaging improvements.

Estate component	Assessment
Active ingredient	Weak due to maturity
Basic liquid scrub	Weak
Specific excipient combination	Moderate only if performance data support narrow claims
Low-irritation formulation	Potentially moderate
Unit-dose or controlled-dispensing package	Moderate
Surgical kit integration	Moderate, with design-around risk
Manufacturing process	Potentially moderate to strong if difficult to reproduce
Trademark and trade dress	Commercially relevant
Trade secrets	Potentially important for process control and scale-up

A defensible follow-on program would use multiple claim layers: composition, concentration ranges, pH, free-iodine availability, viscosity, skin-irritation profile, packaging, dispensing method, and use in defined surgical workflows.

What revenue exposure and commercial upside exist?

Revenue exposure is linked to institutional procedure volume rather than chronic prescription demand. The product can generate recurring use in operating rooms, but price pressure is persistent because hospitals purchase antiseptics through tenders, group purchasing organizations, and distributor contracts.

Commercial upside can come from:

1. Premium low-irritation formulations.
2. Lower total cost per surgical scrub.
3. Ready-to-use unit-dose formats.
4. Integrated surgical preparation kits.
5. International regulatory registrations.
6. Private-label manufacturing.
7. Products designed for high-frequency healthcare-worker use.
8. Sustainable refill and reduced-material packaging.

The most defensible premium is likely to come from measurable workflow or tolerability benefits. A product that uses fewer components, reduces waste, improves dispensing accuracy, or lowers skin complaints can compete even without patent exclusivity.

What is the recommended excipient strategy?

The preferred strategy is a controlled reformulation program with three development tiers:

Tier 1: Low-risk optimization

Retain povidone-iodine 7.5% and optimize:

• Surfactant concentration
• Glycerin level
• Buffer ratio
• pH
• Viscosity
• Foam profile
• Package compatibility

This route offers the fastest path but the lowest IP differentiation.

Tier 2: Differentiated skin-tolerability platform

Develop a lower-irritation surfactant and humectant system with comparative data from the current product. The target profile should include reduced transepidermal water loss, reduced irritation scores, satisfactory cleansing, and unchanged iodine performance.

This route has stronger commercial value and a better basis for formulation patents.

Tier 3: Delivery-system platform

Combine the optimized formulation with:

• Unit-dose sponge applicators
• Closed refill pouches
• Controlled-volume pumps
• Low-waste dispensing
• Procedure-specific kits

This approach can create package and method-of-use claims while improving hospital procurement economics.

Key Takeaways

• BD E-Z SCRUB is a 7.5% povidone-iodine surgical scrub with a conventional surfactant, humectant, buffer, pH-adjustment and water system.
• The product has limited practical patent exclusivity and no clear single patent-expiration event governing market entry.
• Orange Book and Paragraph IV litigation are not the central competitive issues.
• The most valuable excipient opportunity is a lower-irritation surfactant and humectant system that preserves iodine availability.
• Packaging, dispensing, unit-dose formats and surgical-kit integration may offer stronger differentiation than the basic liquid formulation.
• Generic and private-label competition is structurally high.
• Manufacturing know-how, iodine stability, packaging compatibility and hospital qualification are the principal entry barriers.
• A follow-on formulation program should combine composition, process, packaging and method-of-use protection.

FAQs

Is BD E-Z SCRUB a chlorhexidine product?

No. BD E-Z SCRUB is identified as a povidone-iodine 7.5% surgical scrub. Chlorhexidine surgical scrubs are competing products with different antimicrobial chemistry and residual-activity profiles.[1]

Can the surfactant in BD E-Z SCRUB be replaced?

Yes, but replacement requires evaluation of foam, cleansing, iodine availability, pH, viscosity, skin irritation, stability, microbial quality and package compatibility. A simple excipient substitution is unlikely to be commercially sufficient without comparative performance data.

Is povidone-iodine protected by a U.S. drug patent?

The active ingredient is mature and widely used. Commercial protection for a particular product is more likely to depend on branding, manufacturing quality, packaging, contracts and formulation details than on a basic povidone-iodine patent.

Could a BD E-Z SCRUB reformulation receive new patent protection?

Potentially. Protection is more credible for a defined low-irritation composition, controlled free-iodine profile, specialized dispensing package, or validated manufacturing process than for a routine change in glycerin, buffer or water content.

What is the best commercial format for a next-generation product?

A ready-to-use, low-irritation formulation in a unit-dose or closed dispensing system is the strongest combined opportunity. It can address staff tolerability, dosing consistency, contamination control, material waste and hospital procurement economics.

References

1. DailyMed. (n.d.). BD E-Z SCRUB: Povidone-iodine 7.5% surgical scrub labeling. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

3. U.S. Food and Drug Administration. (2016). Safety and effectiveness of consumer antiseptic washes; final rule. Federal Register, 81 Fed. Reg. 61106. https://www.federalregister.gov/

4. U.S. Food and Drug Administration. (2019). Safety and effectiveness of health care antiseptics; topical antimicrobial drug products for over-the-counter human use. Federal Register. https://www.federalregister.gov/

5. U.S. Food and Drug Administration. (2022). Over-the-counter monograph M003: Antiseptic. https://www.accessdata.fda.gov/